Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2018, Vol. 45 Issue (4): 591-593    DOI: 10.12891/ceog4340.2018
Case Report Previous articles | Next articles
Treatment using tadalafil for dichorionic diamniotic twin pregnancy with fetal growth restriction
H. Tanaka1, *(), S. Maki1, M. Kubo1, H. Yuasa2, T. Umekawa1, T. Ikeda1
1 Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
2 Department of Pathology, Mie University School of Medicine, Mie, Japan
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Fetal growth restriction (FGR) is the most important cause of perinatal morbidity and mortality in developed countries. Clinicians are often forced to end the pregnancy due to fetal indications, inflicting iatrogenic prematurity on a fetus with associated high risk of adverse neonatal outcomes. Here, the authors report a case of dichorionic diamniotic (DD) twin pregnancy with FGR whose pregnancy was successfully prolonged using tadalafil, a phosphodiesterase 5 inhibitor. A 22-year-old primigravid woman presented at 25 5/7 weeks of gestation with DD twin pregnancy with FGR. Tadalafil administration was begun at this time. Her pregnancy was prolonged by 90 days after initiation of tadalafil. Tadalafil may be a novel treatment to prolong the period of pregnancy in cases of DD twin pregnancy with FGR and threatened premature labor.
Key words:  Dichorionic diamniotic twin pregnancy      Fetal growth restriction      Tadalafil      Threatened premature labor     
Published:  10 August 2018     
*Corresponding Author(s):  H. TANAKA     E-mail:  h_tanaka@med.miyazaki-u.ac.jp

Cite this article: 

H. Tanaka, S. Maki, M. Kubo, H. Yuasa, T. Umekawa, T. Ikeda. Treatment using tadalafil for dichorionic diamniotic twin pregnancy with fetal growth restriction. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 591-593.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4340.2018     OR     https://ceog.imrpress.com/EN/Y2018/V45/I4/591

[1] N. Wibowo, R. Irwinda, A.T. Rivai. Serum zinc, selenium, iron, and copper levels in pregnant women with fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 892-896.
[2] S. Magawa, H. Tanaka, S. Maki, M. Nii, T. Umekawa, T. Ikeda. Effects of tadalafil on the uterine artery of fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 833-835.
[3] Yajing Zhu, Hongmei Ma, Wei Ma. Transthyretin and retinol-binding protein 4 in patients with fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 270-273.
[4] M. Al-Azemi, R. Raghupathy, F. Azizieh. Pro-inflammatory and anti-inflammatory cytokine profiles in fetal growth restriction[J]. Clinical and Experimental Obstetrics & Gynecology, 2017, 44(1): 98-103.
No Suggested Reading articles found!